Company
Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Sarepta Therapeutics

Main focus: Gene therapies and gene editing for the treatment of muscular dystrophy

Company stage: Clinical

Diseases: Duchenne Muscular Dystrophy (DMD)

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:SRPT)

Location: Cambridge, MA, USA

Website: https://www.sarepta.com/

Pipeline: https://www.sarepta.com/products-pipeline/pipeline

Partnerships: Genevant Sciences, GenEdit

Sarepta Therapeutics is a clinical stage, publicly traded biotech company. The company focuses on many biotherapeutic areas, some of which include gene editing. Sarepta is using CRISPR-Cas9 as a tool for treating Duchenne muscular dystrophy. It has a collaboration with Genevant Sciences for the delivery of CRISPR constructs and collaborations with Duke University and Harvard University to develop gene-editing methods.

Tags

HashtagSarepta Therapeutics

The CMN Collection of Delivery Articles
Company: Sarepta Therapeutics
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine